Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 5/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.45 |
| ▸ | HTR2C | P28335 | 4/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863663 | 0.94 | HTR2C (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Hydrochloric Acid SCHEMBL10502567 | 0.93 | HTR2C (0.44) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Hydrochloric Acid SCHEMBL10502742 | 0.87 | HDAC3 (0.44) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Hydrochloric Acid SCHEMBL10502741 | 0.87 | HDAC3 (0.44) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10366330 | 0.85 | KDM4E (0.44) | HTR2CKDM4EHTTATMAHR | |
| SCHEMBL10607243 | 0.85 | KDM4E (0.44) | HTR2CKDM4EHTTATMAHR | |
| SCHEMBL5321592 | 0.82 | HTR2C (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL25337824 | 0.82 | HTR2C (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL863351 | 0.79 | OPRD1 (0.44) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12569082 | 0.76 | HDAC3 (0.38) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440563-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20120077802-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077802-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077802-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2010144571-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077802-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | HDAC3 637/4885HDAC4 807/4885HDAC1 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.